Skip to main content

Advertisement

Announcement: COVID-19 impact on peer review

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

Featured article: Comprehensive longitudinal study of epigenetic mutations in aging

New Content ItemThe role of DNA methylation in aging has been widely studied. However, epigenetic mutations, here defined as aberrant methylation levels compared to the distribution in a population, are less understood. Our authors investigated longitudinal accumulation of epigenetic mutations, using 994 blood samples collected at up to five time points from 375 individuals in old ages.

Articles

2019
Pollution and Epigenetics
First published: 21 January 2019
Edited by: Steven Gray and Wim Vanden Berghe

2018
Cross-journal collection
Pluripotent Stem Cells
First published: 19 July 2018

2016

Cross-journal collection
Asthma Genetics and Epigenetics
Collection first published: 19 October 2016

Epigenetic Drugs
Edited by: Lucia Altucci & Marianne Rots
First published: 23 May 2016

2015

Breakthroughs in clinical epigenetics
Edited by: Marianne Rots
First published: 1 March 2015

 

Featured Collection

New Content Item © Credit: David Holt (CC BY 2.0)The first articles in our thematic series on Pollution and Epigenetics have published. The Editors are still accepting submissions to the series for the next couple of months.

Submit your research on pollution and epigenetics today.

Graphical Abstracts Now Available

Authors submitting to Clinical Epigenetics now have the option to include a Graphical Abstract when they submit their manuscript.  An image may be uploaded during submission which, together with the article title and abstract text, should provide the reader with a visual description of the topic covered in the article. Graphical abstracts will appear in the HTML version of the article (but not in the PDF version). Instructions for including graphical abstracts is available in the Submission Guidelines for the appropriate article types.

Upcoming Meetings

New Content Item4th International Conference on Epigenetics and Bioengineering (EpiBio 2020

October 9-11, 2020 in North Carolina (North Carolina State University)

Editors-in-Chief

Lucia AltucciUniversità degli Studi della Campania, Italy
Marianne RotsUniversity Medical Center Groningen, Netherlands  

Aims & Scope

Encompassing the broad spectrum of epigenetics research from basic research to innovations in therapeutic treatments, Clinical Epigenetics is a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment. The journal particularly welcomes submissions involving clinical trials, translational research, new and innovative methodologies and model organisms providing mechanistic insights. The journal is divided into the following sections:

  • Aging and development epigenetics
  • Allergy, immunology, and pathogen epigenetics
  • Cancer epigenetics and diagnostics
  • Cardiovascular epigenetics
  • Endocrinology and metabolic epigenetics
  • Environmental epigenetics
  • Epigenetic biomarkers
  • Epigenetic technologies
  • Epigenetic therapies and clinical trials
  • Innovative therapies
  • Lifestyle epigenetics
  • Neurology and psychiatry epigenetics
  • Regenerative medicine
  • Reproductive and transgenerational epigenetics

For more information on the section aims and scope visit our section information page. If you are unclear which section would be best suited to your submission, we invite you to submit a pre-submission inquiry by selecting the Contact Us option here. Please note our new policy regarding submissions involving RNA in our instructions to authors.

Editorial Policy Regarding Submissions Focusing on Non-coding RNAs or RNA Modifications

Manuscripts focusing on differential RNA expression levels (coding or non-coding) or on RNA modifications cannot be considered for publication in Clinical Epigenetics since these aspects are not part of epigenetics per se.

In general, non-coding RNAs affect their target genes at the RNA level, which classifies these molecules as post-transcriptional gene expression regulators. The chromatin effects induced by some ncRNA do not yet justify this, to be included as a general mechanism of action of non-coding RNAs. Similarly, although modifications of RNA molecules resemble modifications of DNA or histone proteins, so do post-translational modifications of non-chromatin proteins. As such, RNA modifications are a novel class of markers, but they are not different from general posttranslational protein modifications (which also are not considered part of epigenetics).

For manuscripts on non-coding RNAs or RNA modifications to be considered for publication in Clinical Epigenetics, the authors must provide at least one of the following:

  • data on the molecular epigenetic regulation of the expression of non-coding RNA (or its modifying enzymes); or
  • insights on the mechanism of action of the non-coding RNA on the chromatin and/or functioning of the DNA; or
  • insights in mitotic stability of the RNA-induced effect.

Archival Content

In October 2011, Clinical Epigenetics became a fully open access journal and is now published as part of BioMed Central's portfolio of journals. To view the journal's content prior to this transition, please see SpringerLink.

Advertisement

Annual Journal Metrics

Advertisement